181 related articles for article (PubMed ID: 37020040)
21. Ovarian Cancer-Insights into Platinum Resistance and Overcoming It.
Havasi A; Cainap SS; Havasi AT; Cainap C
Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984544
[TBL] [Abstract][Full Text] [Related]
22. Phosphoproteomics Analysis Identifies Novel Candidate Substrates of the Nonreceptor Tyrosine Kinase,
Goel RK; Paczkowska M; Reimand J; Napper S; Lukong KE
Mol Cell Proteomics; 2018 May; 17(5):925-947. PubMed ID: 29496907
[TBL] [Abstract][Full Text] [Related]
23. Seeking a better understanding of the non-receptor tyrosine kinase, SRMS.
Goel RK; Kim N; Lukong KE
Heliyon; 2023 Jun; 9(6):e16421. PubMed ID: 37251450
[TBL] [Abstract][Full Text] [Related]
24. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
[TBL] [Abstract][Full Text] [Related]
25. Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer.
Musa F; Alard A; David-West G; Curtin JP; Blank SV; Schneider RJ
Mol Cancer Ther; 2016 Jul; 15(7):1557-67. PubMed ID: 27196780
[TBL] [Abstract][Full Text] [Related]
26. Serum- and glucocorticoid- inducible kinase 2, SGK2, is a novel autophagy regulator and modulates platinum drugs response in cancer cells.
Ranzuglia V; Lorenzon I; Pellarin I; Sonego M; Dall'Acqua A; D'Andrea S; Lovisa S; Segatto I; Coan M; Polesel J; Serraino D; Sabatelli P; Spessotto P; Belletti B; Baldassarre G; Schiappacassi M
Oncogene; 2020 Oct; 39(40):6370-6386. PubMed ID: 32848212
[TBL] [Abstract][Full Text] [Related]
27. Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment.
van Zyl B; Tang D; Bowden NA
Endocr Relat Cancer; 2018 May; 25(5):R303-R318. PubMed ID: 29487129
[TBL] [Abstract][Full Text] [Related]
28. Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts.
Ricci F; Guffanti F; Damia G; Broggini M
Mol Cancer; 2017 May; 16(1):97. PubMed ID: 28558767
[TBL] [Abstract][Full Text] [Related]
29. Ovarian high-grade serous carcinoma cells with low SMARCA4 expression and high SMARCA2 expression contribute to platinum resistance.
Kido K; Nojima S; Motooka D; Nomura Y; Kohara M; Sato K; Ohshima K; Tahara S; Kurashige M; Umeda D; Takashima T; Kiyokawa H; Ukon K; Matsui T; Okuzaki D; Morii E
J Pathol; 2023 May; 260(1):56-70. PubMed ID: 36763038
[TBL] [Abstract][Full Text] [Related]
30. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
31. TAp73-mediated the activation of c-Jun N-terminal kinase enhances cellular chemosensitivity to cisplatin in ovarian cancer cells.
Zhang P; Liu SS; Ngan HY
PLoS One; 2012; 7(8):e42985. PubMed ID: 22900074
[TBL] [Abstract][Full Text] [Related]
32. Secreted Soluble Factors from Tumor-Activated Mesenchymal Stromal Cells Confer Platinum Chemoresistance to Ovarian Cancer Cells.
Koren Carmi Y; Khamaisi H; Adawi R; Noyman E; Gopas J; Mahajna J
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175439
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer.
Quinn JM; Greenwade MM; Palisoul ML; Opara G; Massad K; Guo L; Zhao P; Beck-Noia H; Hagemann IS; Hagemann AR; McCourt CK; Thaker PH; Powell MA; Mutch DG; Fuh KC
Mol Cancer Ther; 2019 Feb; 18(2):389-398. PubMed ID: 30478151
[TBL] [Abstract][Full Text] [Related]
34. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
[TBL] [Abstract][Full Text] [Related]
35. New markers for human ovarian cancer that link platinum resistance to the cancer stem cell phenotype and define new therapeutic combinations and diagnostic tools.
Muñoz-Galván S; Felipe-Abrio B; García-Carrasco M; Domínguez-Piñol J; Suarez-Martinez E; Verdugo-Sivianes EM; Espinosa-Sánchez A; Navas LE; Otero-Albiol D; Marin JJ; Jiménez-García MP; García-Heredia JM; Quiroga AG; Estevez-Garcia P; Carnero A
J Exp Clin Cancer Res; 2019 Jun; 38(1):234. PubMed ID: 31159852
[TBL] [Abstract][Full Text] [Related]
36. Platinum-induced mitochondrial OXPHOS contributes to cancer stem cell enrichment in ovarian cancer.
Sriramkumar S; Sood R; Huntington TD; Ghobashi AH; Vuong TT; Metcalfe TX; Wang W; Nephew KP; O'Hagan HM
J Transl Med; 2022 May; 20(1):246. PubMed ID: 35641987
[TBL] [Abstract][Full Text] [Related]
37. Platinum Resistance After PARPi Resistance in a gBRCAmt Recurrent Ovarian Cancer Patient: a Case Report.
Zhao Q; Ni J; Dong J; Cheng X; Xiao L; Xue Q; Xu X; Guo W; Chen X
Reprod Sci; 2023 Feb; 30(2):615-621. PubMed ID: 35943701
[TBL] [Abstract][Full Text] [Related]
38. Theasaponin E
Li B; Tong T; Ren N; Rankin GO; Rojanasakul Y; Tu Y; Chen YC
Molecules; 2021 Mar; 26(6):. PubMed ID: 33802884
[TBL] [Abstract][Full Text] [Related]
39. Predicting Prognosis and Platinum Resistance in Ovarian Cancer: Role of Immunohistochemistry Biomarkers.
Atallah GA; Kampan NC; Chew KT; Mohd Mokhtar N; Md Zin RR; Shafiee MNB; Abd Aziz NHB
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768291
[TBL] [Abstract][Full Text] [Related]
40. TR3 modulates platinum resistance in ovarian cancer.
Wilson AJ; Liu AY; Roland J; Adebayo OB; Fletcher SA; Slaughter JC; Saskowski J; Crispens MA; Jones HW; James S; Fadare O; Khabele D
Cancer Res; 2013 Aug; 73(15):4758-69. PubMed ID: 23720056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]